The Future of Cell Therapy

FibroBiologics is a cell therapy biotech and pharmaceutical company with over 13 years of R&D and clinical development. The company’s first product may be approved as early as 2023, alongside clinical trials for additional treatments.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$4,999,986.66 Raised


Reasons Icon

FibroBiologics controls over 160 U.S. and international patents across a variety of clinical pathways, driven by a team with decades of medical product and business experience.

Reasons Icon

The company has five product candidates in the pipeline targeting different medical areas: multiple sclerosis ($27B market size), degenerative disc disease ($90B), wound healing ($50B), cancer ($286B), and extension-of-life applications.*

Reasons Icon

FibroBiologics is the global leader in developing fibroblasts as a cell therapy technology platform. Compared with stem cells, fibroblasts are much easier to harvest, grow, store, and transport.

*Market analysis conducted internally using research provided by Fortune Business Insights & Precedence Research (source)

the pitch

Nearly every medical professional can agree, cell therapy is critical to the future of fighting chronic disease. At FibroBiologics, we’ve keyed in on a specific, widely accessible cell type that holds seemingly endless curative potential. Fueled by innovation and urgency, FibroBiologics has obtained or submitted over 160 patents, completed over 13 years of R&D, and has raised $40M to date for the development of our intellectual property portfolio. Our targets for breakthrough treatments include multiple sclerosis, degenerative disc disease, wound healing, cancer, and extension-of-life applications.  

Pioneering the Next Generation of Curative Medicine

Founded two years ago, FibroBiologics is now a leading biopharma company focused on developing and commercializing fibroblast cell-based therapies in the fight against chronic diseases. 

We’ve dedicated our attention to an overlooked and highly promising cell therapy using fibroblasts, which demonstrate similar characteristics to stem cells and are one of the most abundant cells in the human body. 

Through our research and product development, we are fundamentally changing the current treatment paradigm and shaping the future for how we fight chronic disease.

The Problem & Our Solution

An Advantageous Alternative to Stem Cell Therapies

Up to this point, cell therapy research has primarily focused on the use of stem cells, with over 30 companies currently participating in the space, yet stem cells are not the only option for cell therapy treatment. Research has shown that fibroblasts have similar capabilities to stem cells, although fibroblasts are more readily available, more robust, and less expensive. They are also much easier to harvest, grow, store, and transport—all in all, improving outcomes and reducing patient barriers to access.

FibroBiologics is developing fibroblast cell therapy platform technology, with an extensive patent portfolio covering a wide range of clinical applications. The company is currently conducting research to discover potential breakthrough treatments and cures of chronic diseases, which we will continue to develop into product candidates by conducting clinical studies and trials to demonstrate safety and efficacy. We will generate revenues by either commercializing approved products on our own or by partnering with biopharma companies that will develop and commercialize these product candidates and pay us licensing revenues. 

*Information provided by Fortune Business Insights & Precedence Research (source)

The company currently has five product candidates in the pipeline targeting different medical areas: multiple sclerosis ($27B market size), degenerative disc disease ($90B market size), wound healing ($50B market size), cancer ($286B market size), and extension-of-life applications.*

*Market analysis conducted internally using research provided by Fortune Business Insights & Precedence Research (source)

The Market & Our Traction

Medical Breakthroughs for Massive Market Potential

The combined market size of the breakthrough treatments we are targeting is over $450B*, and we believe that’s just the tip of the iceberg. Anyone who’s been paying attention has seen the excitement and investment spurred by breakthroughs in stem cell research and accompanying medical advances—and for fibroblasts, we expect we’re looking at equally attractive potential. 

*Market analysis conducted internally using research provided by Fortune Business Insights & Precedence Research (source)

Each of our product candidates exists within a multi-billion-dollar global market with enormous growth potential, thanks to increasing access on a global scale and aging populations. To date, FibroBiologics and our parent company, SpinalCyte, LLC, have raised $40M for the development of our intellectual property portfolio for fibroblast cell therapy, completed over 13 years of R&D, and we’ve secured or submitted over 160 patents (and counting).

*Market analysis conducted internally using research provided by Fortune Business Insights & Precedence Research (source)

The company has received IND clearance for phase 1/2 study in degenerative disc and planning for an IND submission for multiple sclerosis indications.. As early as 2023, we may have an approved product in wound healing, and with adequate capital, we’ll initiate clinical trials for degenerative disc and multiple sclerosis treatments, as well as beginning discovery research in cancer and extension-of-life applications. 

Why Invest

Invest in the Future of Treating Chronic Disease

The potential of our fibroblast cell-based therapy has game-changing health implications and potential opportunity for our investors. Your investment would bring us one step closer to a breakthrough in our treatment of chronic diseaseJoin us in leading the new era of cell therapy, and invest in FibroBiologics today!

FibroBiologics 17b Disclosure


455 E. Medical Center Blvd, Suite 300
Houston, TX 77598

FibroBiologics is a cell therapy biotech and pharmaceutical company with over 13 years of R&D and clinical development. The company’s first product may be approved as early as 2023, alongside clinical trials for additional treatments.


Peter O'Heeron
Peter O'Heeron
CEO/Founder/Chairman of Board

Pete O’Heeron is one of the most preeminent inventors of his generation, with over 300+ patents issued and pending in the areas of biologics, cell therapy and medical devices. Mr. O’Heeron is Chief Executive Officer of FibroBiologics and a seasoned leader in his field with over 25 years of experience in medical technology and biotech development. As CEO, he has positioned FibroBiologics to become a global leader in fibroblast-based cell therapies with the development and commercialization of therapies that can cure and treat patients suffering from chronic diseases. He brings together multi-disciplinary teams and resources necessary to commercialize unique technologies with over $300 million in funding raised.

Prior to founding FibroBiologics/FibroGenesis, LLC, he founded an operational investment group, Advanced Medical Technologies, LLC, that identified early-stage opportunities in the medical field with strong intellectual property potential. He also founded NeoSurg Technologies that developed the T2000 Minimally Invasive Access System. The sale of NeoSurg Technologies to Cooper Surgical occurred in 2006.

He brings decades of executive-level experience at Christus Health Care Corporation and strategic advisory to healthcare companies in the areas of biologics, advanced surgical instrumentation, and telemedicine to his company along with an academic foundation rooted in healthcare administration. He received his Bachelor’s Degree in Healthcare Administration at Texas State University, his Masters in Healthcare Administration from the University of Houston Clear Lake, and his Executive Management Certification in Mergers and Acquisition from University of Chicago.

Mark Andersen

Mark Andersen


Mark Andersen, CFA, CPA, joined FibroBiologics as Chief Financial Officer in June 2022. He is a key member of the FibroBiologics executive leadership team and plays a critical role in the company’s strategic financial decision-making.

He most recently served as Chief Financial Officer and Vice President of Administration for the Indiana Biosciences Research Institute (IBRI) in Indianapolis, overseeing finance, human resources, legal, and administrative functions. While at IBRI, he negotiated a master licensing agreement and in-licensed two patents to help establish a platform diagnostics technology. He also assisted with fundraising and provided oversight for the endowment investment portfolio that grew to nearly $150 million during his tenure. Prior to that, he served as Vice President of Finance and Corporate Controller for a public biomedical company in Georgia where he was responsible for financial accounting and SEC reporting.

He served in various financial leadership positions at Eli Lilly and Company in Global Treasury, Mergers and Acquisitions, Lilly USA, Corporate Financial Reporting, and Global Product Development. At Lilly, he managed investment portfolios, led M&A transactions, provided financial leadership and negotiation support for licensing deals, and directed all financial aspects of a collaborative partnership during the late-stage development and commercial launch of a first-in-class diabetes drug. He started his career in public accounting as an auditor with firms KPMG and Deloitte.

He received his M.B.A. from the University of Michigan Ross School of Business and his B.S. in Accounting and M.S. in Accountancy from Southern Utah University.

Hamid Khoja

Hamid Khoja

Chief Scientific Officer

Hamid Khoja, Ph.D. joined FibroBiologics as Chief Scientific Officer in August 2021. He leads all research, development, and advancement for the pipeline of cell therapy candidates. He has more than 25 years of experience as a leader of scientific teams, development of cell-based genomic, proteomic, epigenetics assays, and tools, protocols, and technologies for use in drug discovery and development and clinical diagnostics.

He has distinguished himself with six patents issued/pending and 27+ peer reviewed published papers.

He most recently served as the Principal Scientist at Covaris, a privately held scientific tools company with emphasis in genomics, epigenetics, and proteomics. He provided long-term strategic applications proposals to the CEO, managed external collaborations for product and applications development, assessed new technologies for acquisition and OEM opportunities, and presented posters and presentations at numerous scientific conferences. He led the effort in successfully incorporating Covaris technology into the Illumina Next Generation Sequencing technology protocols leading to over 15,000+ citations. He also developed the Covaris chromatin immunoprecipitation methodology with 3,000+ citations in peer reviewed publications and positioned Covaris technology to be used for simplifying epigenetics assay workflows for use in drug development and discovery and clinical use. He led collaborations with NCI for successful development of microbiome DNA extraction using acoustics and the completion of FDA EUA SARA-CoC-2 bridge study design for approval of new sample collection and viral RNA extraction using Covaris technology. He developed a patented workflow for the manufacturing of synthetic cell-free DNA for use as reference standard in sequencing-based liquid biopsy clinical oncology-based assays.

Prior to Covaris, he was a scientist at Genomic Solutions, a startup scientific tools company later acquired by Harvard Apparatus. There, he led the development of a high throughput protein crystallization platform used in the pharmaceutical industry for drug development, managed the scientific applications group, presented company resources at scientific meetings, and assessed new technologies for acquisition and OEM opportunities.

At the startup phase of Sequenom, he established the methodology for a highly multiplexed PCR used in the development of Sequenom’s massEXTEND technology for MALDI-TOF MS-based analysis of single nucleotide polymorphisms and genetic disease. As a scientist for the company, he led the effort in developing diagnostic MS-based assays for hemochromatosis, cystic fibrosis, and 10 predominantly Jewish genetic diseases using Sequenom’s massEXTEND technology, which were then transferred to a large clinical diagnostic company.

During his career at Eli Lilly as a scientist, he established a high throughput PCR and sequencing strategy using a variety of sequencing strategies and bioinformatic tools available in 1999 for obtaining high-coverage genome sequencing, which led to the finalization of the first ever complete sequence of the S. pneumoniae genome.

At Chiron Corporation, subsequently acquired by Novartis, he served as a scientist and helped in the design, development, and optimization of HTP- binding assays for FGFR, VEGF, PDGF, and EPO receptors. He also helped in the identification of novel g-protein coupled seven transmembrane receptors, novel proteins involved in the TNF signaling pathway, and development of branched-DNA based HTP screening for ligand-induced oncogene quantification.

He graduated magna cum laude with a Bachelor of Science in Molecular Biology from the University of Southern California and a Ph.D. in Molecular Biology from Boston University.

Richard Cilento Jr.

Richard Cilento Jr.


Rich Cilento has more than 25 years of domestic and international business experience across a broad set of highly technical industries. Rich has led companies in nearly every stage of the business life cycle. An Aeronautical & Astronomical Engineer; Rich’s life sciences experiences began as a Space Shuttle Flight Controller at the Johnson Space Center, where he built Space Shuttle flight plans for the Department of Defense Star Wars program and a diverse set of government-funded technology and life science experimentation. Rich was a lead engineer who designed and planned the Space Station assembly sequences for the construction of the International Space Station.

Rich has executive-level knowledge of capital markets, including venture capital, private equity, and public markets with IPO experience. Rich received the prestigious honor, winning the Ernst and Young Entrepreneur of the Year Award. From a Board member perspective, he has always enjoyed mentoring Entrepreneurs, CEOs, and Ph.D.’s developing purpose-driven, high-growth business ventures across a diverse set of markets. As a Board member for Mercury Data Science, Rich is supporting this innovative life science focused company using artificial intelligence and machine learning to improve care and enhance therapeutic discoveries with artificial intelligence and machine learning by integrating computational biology, genomics, bioinformatics, and physics.

As Chairman & CEO of GlycosBio, Inc., Rich is leading a mission to nourish and enhance the lives of people at all stages of life with a focus on fragile populations struggling with microbiome dysbiosis. GlycosBio scientists also work to reduce the dependence of antibiotics and prescription medication on children using novel natural antimicrobial and antiviral technologies. An ag-tech enthusiast and farmer, Rich enjoys Non-GMO farming in Illinois. Ethical investments are focused on leveraging the natural resources of Ghana, Africa to improve the quality of life and the economic development of the local Ghana community. Rich help fund the construction and operations of a water purification and production factory in Kumasi that provides safe drinking water in the region. Rich has also contributed to clean technology, medical sciences, pharmaceutical, higher education, and space sectors as an angel investor.

Rich was the Founder, President and Chief Executive Officer of FuelQuest, Inc. (acquired by Saracen). Rich led ZyTax Inc. a technology company that developed into the largest excise tax platforms (acquired by Avalara Software, NYSE). As a public company Officer, he supported the IPO of XL Connect Solutions (Nasdaq), where he led the technology-enabled SaaS business for XL Connect (acquired by Xerox). He held Senior Executive level positions for Xerox Corporation (NYSE).

Stacy Coen

Stacy Coen

Board Member

Mrs. Coen brings over 20 years of business and corporate development experience from leading oncology and rare disease companies. She is currently the Chief Business Officer for ImmunoGen, a company that is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Prior to ImmunoGen, Mrs. Coen worked at Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. While at Editas, Mrs. Coen worked on various transactions to enable company progress in the cell therapy field. Prior to joining Editas, Mrs. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Mrs. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.

Robert Hoffman

Robert Hoffman

Board Member

Robert E. Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fundraising, strategic planning, corporate governance, investor relations, and leadership.

Robert is the President, CEO and Chairman of Kintara Therapeutics, Inc. (NASDAQ: KTRA). Robert presently sits on two publicly-traded company boards (ASLAN Pharmaceuticals – Nasdaq: ASLN and Antibe Therapeutics – TSX: ATE) serving as Chairman of the Board of Antibe and as audit committee chair on ASLAN. In his previous operating role, Robert was CFO of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. Robert’s career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he was a member of the founding management team and rose to become CFO, holding that position for ten years. While at Arena, he was involved in its IPO and financings, raising more than $1.5 billion. Robert was the financial lead in two Arena acquisitions, including a Swiss manufacturing facility that he became managing director of the facility upon the closing of the transaction. Robert was an advisor to the Financial Accounting Standard Board (FASB) for 10 years (2010 to 2020) advising the United States accounting rulemaking organization on emerging issues and new financial guidance. Charity work is important to Robert. As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Robert has served on its board of directors for 20 years. Robert received his BBA in accounting from St. Bonaventure University and is a licensed CPA (Inactive) in the State of California.

Matthew Link

Matthew Link

Board Member

Matt Link served as NuVasive’s President (NUVA $3.3B Market Cap), overseeing Global Logistics, NuVasive Clinical Services, Surgical Intelligence, Global Implant Systems, NuVasive Specialized Orthopedics, Strategy & Corporate Development, Global Marketing, Medical Affairs, and Clinical Professional Development. His prior roles at NuVasive include President of Strategy, Technology, and Corporate Development; President, U.S. Commercial; Executive Vice President of U.S. Sales; Senior Vice President of Sales for the Company’s U.S. Eastern region; and several regional sales positions with DePuy Orthopedics and DePuy Spine. Mr. Link received a BSEd in Physical Education and Sports Medicine from the University of Virginia.

Victoria Niklas

Victoria Niklas

Board Member

Dr. Victoria Niklas is a Global Biotechnology Executive with a distinguished career spanning more than two decades in translational research and clinical medicine in academic health centers.

She earned her Doctor of Medicine at Harvard Medical School, a Master’s Degree in Biochemistry and Molecular Biology from Harvard University, and a Master’s Certificate in Academic Medicine & Leadership from the USC Keck School of Medicine, Los Angeles. Victoria has held academic professorial appointments at the University of Virginia, Charlottesville, the Keck School of Medicine at the University of Southern California, Los Angeles, and the David Geffen School of Medicine at UCLA. As an experienced clinician investigator and neonatologist, she is highly skilled in aligning basic and translational science with unmet clinical needs in the path to drug discovery. Her expertise spans developmental and acquired disorders of the gut, the lung, the immune system focusing on innovative therapies for diseases with no cure. 

Victoria brings a passion and broad understanding of science and medicine to biopharmaceutical drug exploration and clinical development in her role at Takeda Pharmaceuticals. Her efforts create and deliver meaningful medical solutions to improve patient outcomes and health. As an industry thought leader with a broad knowledge base, Dr. Niklas has co-authored numerous scientific and clinical publications in peer-reviewed journals and participated as a speaker and chair in international conferences. She has led the development of patented products and has served as a board member for hospital and medical organizations and committees. She is board certified in Perinatal and Neonatal Medicine and holds an active California medical license. Dr. Niklas is an exceptional medical professional, scientific leader, and superb communicator for corporate biotechnology and healthcare.


May 2, 2023
Series B Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income





FibroBiologics, Inc.

Corporate Address


455 E. Medical Center Blvd, Suite 300, Houston, TX 77598

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Series B Preferred Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.


Friends and Family Early Birds

Invest $25,000+ within the first 72 hours and receive 10% bonus shares

Early Bird Bonus

Invest $1,000 within the next two weeks and receive 5% bonus shares


$25,000+ | Tier 1

Invest $25,000+ and receive 5% Bonus Shares.

$100,000+ | Tier 2

Invest $100,000+ and receive 10% Bonus Shares.

Loyalty Bonus:

Existing shareholders of FibroBiologics who have committed to making additional investment in this round will receive 10% bonus shares

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Fibrobiologics, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Series B Preferred Stock at $1.69 / share, you will receive 100 shares of Series B Preferred Stock, meaning you'll own 110 shares for $169. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.



On the Verge of Hitting our Maximum Amount on this Reg CF Round

In less than 4 weeks, we are getting close to our maximum raise of $5M.  Thanks to all of our new shareholders!  We welcome you to our mission of finding a cures for chronic diseases!

Pete O'Heeron, Founder/CEO


FibroBiologics Sets Another Record as Highest Amount Raised per Biotech Investor in History

FibroBiologics Sets Another Record as Highest Amount Raised per Biotech Investor in History 


HOUSTON, February 24, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced they have raised the highest amount per biotech investor in StartEngine history surpassing $6,900/investor as an average investment size. StartEngine is one of the largest equity crowdfunding platforms in the U.S., led by Activision Co-Founder Howard Marks and advised by Kevin O'Leary. StartEngine launched in 2015 with the mission to help entrepreneurs achieve their dream while enabling everyday people to access private investment opportunities. To date, over $650 million has been raised for startups and alternative assets on the StartEngine platform from more than 1 million users. 


“We are excited to see that the adoption of this offering by the investment community has surpassed our most optimistic projections,” said FibroBiologics’ Founder and CEO, Pete O’Heeron. “Our dedication to breakthrough science and our commitment to creating cures for chronic diseases using our proprietary cell therapy is creating unprecedented momentum from the StartEngine platform and the amount of ‘inbound’ interest is a tremendous validation of our work for a “next- generation” cell therapy.”


For more information, please visit FibroBiologics' website or email FibroBiologics at To invest in FibroBiologics, please go to the company's campaign on StartEngine



Who We Are


Breakthrough Science for Chronic Wounds!

We just completed an animal trial for our chronic wound program, and our proprietary fibroblast technology improved the healing time over the existing #1 product in the market by a significant amount.  Reducing the time for healing leads to lower infection rates and improved patient outcomes.  Using our proprietary delivery mechanism reduced the healing time even more. Our fibroblasts have shown significant improvement in every phase of the wound healing process.


$3M in 9 Days!

We just surpassed $3M in only 9 days!  The momentum is building and you've joined a team who has dedicated their lives to creating breakthrough science for patients suffering from chronic diseases using fibroblasts.  We are working toward cures for multiple sclerosis, cancer, degenerative disc disease, wound care and extension-of-life.  Please keep telling your friends!

Best wishes,

Pete O'Heeron, Founder/CEO


Wow Over $2.5M

We're so excited our unique cell therapy platform is generating so much interest!  The offering has only been "live" for a week and we just went over $2.5M in capital raised!  As the fastest rising biotech in StartEngine history, your involvement extends this historic momentum.

Please continue to spread the word and look back soon for more updates!

Best wishes,

Pete O'Heeron, Founder/CEO


We just passed $2M!

I want to welcome all new shareholders to our mission of developing cures for chronic diseases using our proprietary cell therapy platform. The interest in our company was demonstrated by becoming the fastest rising biotech in StartEngine history.  The momentum is a credit to your commitment and we look forward to growing this exciting science with you as a shareholder!  Have a great weekend and tell your friends to check us out on StartEngine.  

See our announcement here:  

FibroBiologics Sets a Record


Pete O'Heeron, Founder/CEO


FibroBiologics Sets Record as Fastest Growing Biotech Campaign in StartEngine History

Thank you for investing in FibroBiologics! We are excited to announce we set a record with the most funding raised by a Biotech on the first day in StartEngine history, surpassing $1M. Join our other shareholders as we develop cures for chronic diseases and change peoples' lives.

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into FibroBiologics.


Earn 10% Bonus Shares

Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.


Tier 1

Invest $25,000+ and receive 5% Bonus Shares.


Tier 2

Invest $100,000+ and receive 10% Bonus Shares.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.